• Sumitomo Pharma kept its FY2026 forecasts unchanged.
• Forecasts call for revenue of JPY 540 billion, core operating profit of JPY 91 billion, operating profit of JPY 90 billion.
• Outlook includes profit before taxes of JPY 83.5 billion, net profit attributable to owners of JPY 77 billion.
• Guidance assumes an average exchange rate of USD/JPY 155.
• Q1 revenue rose to JPY 129.5 billion from JPY 108 billion; core operating profit fell to JPY 18.1 billion from JPY 20.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.